Inside the research
Henry Schein, Inc.
HSIC Research profile · latest available data
Price overview
$86.37
▲ +0.84 (+1.0%)
| 52w hi | $90.86 |
|---|---|
| 52w lo | $62.03 |
| Vol | 1.20M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.37
| Short | +0.31 |
|---|---|
| Medium | +0.46 |
| Long | +0.31 |
computed 2026-09-27
Key fundamentals
Henry Schein, Inc.
Healthcare · Medical Distribution
| Market cap | $9.63B |
|---|---|
| Enterprise value | $14.85B |
| Trailing P/E | 25.18x |
| Forward P/E | 14.42x |
| EV / EBITDA | 13.75x |
| P / S (ttm) | 0.72x |
| Profit margin | 3.0% |
| Return on equity | 8.9% |
| Revenue growth | +6.7% |
| Earnings growth | +17.1% |
| Debt / equity | 80.73 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.23 | |
| Sector | +0.08 | |
| Technical | +0.19 | |
| Earnings | +0.00 | |
| Sentiment | +0.10 |
macro × 1.00 · 2026-09-27
Business overview
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Risk Metrics
| Beta vs SPX | 0.58 |
|---|---|
| Corr SPX | 0.34 |
| Annual vol | 27.0% |
| Annual ret | +13.3% |
| Sharpe | 0.49 |
| Max DD | -24.3% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $87.21 |
|---|---|
| High / Low | $100.00 / $64.00 |
| Median | $88.00 |
| Analysts | 14 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 4 | |
| Hold | 7 | |
| Sell | 1 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-06 | UBS | → Neutral |
| 2026-05-06 | Mizuho | → Neutral |
| 2026-04-24 | Morgan Stanley | → Underweight |
| 2026-04-16 | BTIG | → Neutral |
| 2026-04-15 | Citigroup | → Buy |
| 2026-04-08 | Evercore ISI Group | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-07-30 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-22 | Shareholder Vote, Reg FD Disclosure… | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-02-24 | Earnings Release, Exhibits | read |
| 2026-01-12 | Officer / Director Change, Bylaws Amendment… | read |
| 2025-12-23 | Officer / Director Change, Exhibits | read |
| 2025-12-23 | Material Agreement, Material Obligation… | read |
| 2025-12-09 | Material Agreement | read |
| 2025-11-04 | Earnings Release, Exhibits | read |
| 2025-09-09 | Officer / Director Change | read |
| 2025-08-05 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | DANIEL WILLIAM K | Director | Grant | 2.21K | — |
| 2026-03-19 | Popeck Thomas C | Officer, CEO, Henry Schei | Sell | 1.35K | $98.63K |
| 2026-03-17 | Ettinger Michael S | Officer, EVP & Chief Oper | Gift | 1.00K | — |
| 2026-03-16 | Sheehy Christine Zayac | Officer, SVP, Chief Huma | Withheld for tax | 463 | $34.54K |
| 2026-03-16 | Popeck Thomas C | Officer, CEO, Henry Schei | Withheld for tax | 587 | $43.80K |
| 2026-03-16 | MLOTEK MARK E | Officer, EVP, Chief Strat | Withheld for tax | 5.93K | $442.29K |
| 2026-03-16 | Ettinger Michael S | Officer, EVP & Chief Oper | Gift | 1.30K | — |
| 2026-03-16 | Ettinger Michael S | Officer, EVP & Chief Oper | Withheld for tax | 4.21K | $314.41K |
| 2026-03-16 | South Ronald N. | Officer, SVP & Chief Fina | Withheld for tax | 5.22K | $389.17K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 99.9% |
| HHI | 4,027 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Vanguard Group Inc | $875.84M | 11.59M |
| State Street Corp | $332.79M | 4.40M |
| Fidelity / FMR LLC | $300.26M | 3.97M |
| Citadel Advisors | $24.19M | 320.05K |
| Millennium Management | $16.07M | 212.68K |
| AQR Capital Management | $1.25M | 16.57K |
| Bridgewater Associates | $560.27K | 7.41K |
| T. Rowe Price Group | $11.46K | 151.61K |
As of 2025-12-31
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $13.18B | +13.8% | |
| Gross profit | $3.86B | +4.8% | |
| Operating income | $621.00M | +2.0% | |
| Net income | $398.00M | +13.3% | |
| Cash from ops | $500.00M | +2.1% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $85.53 | $86.58 | $85.43 | $86.37 | 1.20M |
| Sep 24 | $84.50 | $85.92 | $84.38 | $85.53 | 1.38M |
| Sep 23 | $86.89 | $87.98 | $84.80 | $85.05 | 1.12M |
| Sep 22 | $85.93 | $87.64 | $85.58 | $87.43 | 1.07M |
| Sep 21 | $85.25 | $85.80 | $84.40 | $85.20 | 1.35M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →